VIDA appoints digital health technology leader Karen Drexler to board of directors

Growing bench of proven leaders in clinical lung intelligence and health technology bolsters both product and commercial advances

CORALVILLE, Iowa, Aug. 11, 2020 /PRNewswire/ — VIDA Diagnostics, Inc. (“VIDA”), the leader in lung and respiratory intelligence, announced today that it is has appointed Karen Drexler to its board of directors, further expanding the company’s leadership strength in digital health technology. Drexler’s appointment comes at a critical time in healthcare, as the world continues to address the potential long-term lung health implications of the COVID-19 pandemic. VIDA, with its suite of AI-powered lung intelligence solutions and analytics, is uniquely positioned to modernize lung and respiratory care for patients with or at risk of a variety of complex lung diseases.

“Karen has a stellar entrepreneurial and operating background in digital health technology, along with an impressive track record of commercial success,” said Susan Wood, Ph.D., president and CEO of VIDA.  “Her addition to the board will further fuel our market expansion during and beyond the COVID pandemic and bolster our mission to modernize lung care.”

Read the full article here.